Synovial fluid assay detecting Lyme bacterial debris after
This technology addresses a persistent problem with Lyme disease: even after antibiotic treatment kills the bacteria, fragments of the bacterial cell wall (called peptidoglycan) can remain in joint fluid and drive ongoing inflammation that looks and feels like treatment failure. The researchers discovered that a human immune protein called NOD2 can be used to directly detect these peptidoglycan fragments in synovial fluid, enabling a specific test for Lyme arthritis. The same insight opens a therapeutic door: antibodies or enzymes that neutralize or destroy these peptidoglycan fragments could potentially resolve post-treatment Lyme arthritis, which currently has no approved targeted therapy.
What you could build
A synovial fluid diagnostic assay for rheumatologists and infectious disease specialists to distinguish active Lyme arthritis from post-treatment inflammatory arthritis; a secondary opportunity exists for a biologic therapeutic (antibody or hydrolase enzyme) targeting residual peptidoglycan in treatment-resistant Lyme patients.
Who in Virginia should care
Virginia-based infectious disease centers, military health systems (Lyme is prevalent in mid-Atlantic tick habitats), and NIH-proximate biotech firms in Northern Virginia focused on diagnostics or biologics would be natural partners or licensees.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Brandon L. JUTRAS, Christine Jacobs-Wagner
- Granted
- January 27, 2026
- Status
- Granted patent
- Patent number
- 12535481
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.